Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
Eris Lifesciences IPO is a book build issue of ₹1,740.49 crores. The issue is entirely an offer for sale of 2.89 crore shares of ₹1,740.49 crore.
Eris Lifesciences IPO bidding started from Jun 16, 2017 and ended on Jun 20, 2017. The allotment for Eris Lifesciences IPO was finalized on Jun 23, 2017. The shares got listed on BSE, NSE on Jun 29, 2017.
Eris Lifesciences IPO price band is set at ₹603.00 per share . The lot size for an application is 24. The minimum amount of investment required by an retail is ₹14,400 (24 shares). The lot size investment for sNII is 14 lots (336 shares), amounting to ₹2,02,608, and for bNII, it is 70 lots (1,680 shares), amounting to ₹10,13,040.
The issue includes a reservation of up to 1,50,000 shares for employees offered at a discount of ₹60.00 to the issue price.
Axis Capital Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue.
Refer to Eris Lifesciences IPO RHP for detailed Information.
| IPO Date | June 16, 2017 to June 20, 2017 |
| Listing Date | June 29, 2017 |
| Face Value | ₹1 per share |
| Issue Price Band | ₹600 to ₹603 per share |
| Issue Price Final | ₹603 per share |
| Lot Size | 24 Shares |
| Sale Type | Offer For Sale |
| Total Issue Size | 2,88,75,000 shares (aggregating up to ₹1,740.49 Cr) |
| Employee Discount | ₹60.00 |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 13,75,00,000 shares |
| Share Holding Post Issue | 13,75,00,000 shares |
Eris Lifesciences IPO offers total 2,88,75,000 shares. Out of which 2,15,43,750 (74.61%) allocated to QIB, 86,17,500 (29.84%) allocated to QIB, 43,08,750 (14.92%) allocated to NII, 28,72,500 (9.95%) allocated to RII and 1,29,26,250 (44.77%) allocated to Anchor investors.
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| QIB Shares Offered | 2,15,43,750 (74.61%) | NA |
| − Anchor Investor Shares Offered | 1,29,26,250 (44.77%) | NA |
| − QIB (Ex. Anchor) Shares Offered | 86,17,500 (29.84%) | NA |
| NII (HNI) Shares Offered | 43,08,750 (14.92%) | NA |
| Retail Shares Offered | 28,72,500 (9.95%) | 1,19,687 |
| Employee Shares Offered | 1,50,000 (0.52%) | NA |
| Total Shares Offered | 2,88,75,000 (100.00%) |
| Application Category | Maximum Bidding Limits | Bidding at Cut-off Price Allowed |
|---|---|---|
| Only RII | Up to Rs 2 Lakhs | Yes |
| Only sNII | Rs 2 Lakhs to Rs 10 Lakhs | No |
| Only bNII | Rs 10 Lakhs to NII Reservation Portion | No |
| Only employee | Yes | |
| Employee + RII/NII |
|
Yes for Employee and RII/NII |
Eris Lifesciences IPO opens on June 16, 2017, and closes on June 20, 2017.
| IPO Open Date | Fri, Jun 16, 2017 |
| IPO Close Date | Tue, Jun 20, 2017 |
| Tentative Allotment | Fri, Jun 23, 2017 |
| Initiation of Refunds | Tue, Jun 27, 2017 |
| Credit of Shares to Demat | Wed, Jun 28, 2017 |
| Tentative Listing Date | Thu, Jun 29, 2017 |
| Cut-off time for UPI mandate confirmation | 5 PM on Tue, Jun 20, 2017 |
Investors can bid for a minimum of 24 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 24 | ₹14,472 |
| Retail (Max) | 13 | 312 | ₹1,88,136 |
| S-HNI (Min) | 14 | 336 | ₹2,02,608 |
| S-HNI (Max) | 69 | 1,656 | ₹9,98,568 |
| B-HNI (Min) | 70 | 1,680 | ₹10,13,040 |
Incorporated in 2007, Eris Lifescience Ltd is Ahmedabad, Gujrat based pharmaceutical company engaged in research, development, manufacturing and selling of select therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market.
Eris product portfolio is primarily focused on therapeutic areas which require the intervention of super specialist and specialist doctors such as Diabetologists, Endocrinologists Cardiologists, and Gastroenterologists.
Eris products in the chronic category cater primarily to the therapeutic areas including cardiovascular, anti-diabetics and neurology, chronic respiratory and chronic pain (analgesics).
In acute category, the product portfolio includes vitamins, gastroenterology, anti-infectives, gynaecology, cute respiratory, acute pain (analgesics), hepatoprotectives, hormones, hematology, dermatology, anti-obesity products and products for injury healing.
Eris Lifescience own and operate a manufacturing facility in Guwahati, Assam. They also outsource the manufacturing of certain of its products to 20 manufacturers. Eris strong sales team comprised of 1,310 marketing representatives.
Eris Lifescience Strengths:
• Focus on branded prescription based pharmaceutical products catering to lifestyle related disorders
• Portfolio of high volume and leading brands
• Focus on metro cities and class 1 towns in India which have higher incidence of lifestyle disorders and concentration of specialists and super specialists
• Multi-faceted product selection and engagement model leading to growth in prescription
• Strong sales, marketing and distribution capabilities
| Particulars | For the year/period ended (in Rs. Million) | |||||
|---|---|---|---|---|---|---|
| 31-Mar-16 | 31-Mar-15 | 31-Mar-14 | 31-Mar-13 | 31-Mar-12 | ||
| Total Assets | 3,973.59 | 3,572.85 | 2,705.99 | 1,718.05 | 1,019.67 | |
| Total Revenue | 5,970.21 | 5,455.58 | 5,088.22 | 3,930.64 | 2,739.40 | |
| Profit After Tax | 1,348.58 | 892.59 | 709.12 | 584.40 | 370.63 | |
The Company Eris Lifesciences IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:
| S.No. | Objects of the Issue | Expected Amount (₹ in crores) |
|---|---|---|
| 1 | The company will not receive any proceeds from the Offer and all the proceeds will go to the Selling Shareholders. |
[Dilip Davda] Investors may consider investment for medium to long term in this niche player having better penetration. Read detail review...
| Listing Date | June 29, 2017 |
| BSE Script Code | 540596 |
| NSE Symbol | ERIS |
| ISIN | INE406M01024 |
| Final Issue Price | ₹603 per share |
| BSE Listing Group | B |
Eris Lifesciences Ltd.
7th Floor, Commerce House IV,
Beside Shell Petrol Pump, 100 Feet Road,
Prahladnagar, Ahmedabad 380 015
Ahmedabad, Gujarat
Phone: +91 79 3045 1111
Email: complianceofficer@erislifesciences.com
Website: http://eris.co.in/
MUFG Intime India Pvt.Ltd.
Phone: +91-22-4918 6270
Email: eris.ipo@linkintime.co.in
Website: https://linkintime.co.in/Initial_Offer/public-issues.html
Eris Lifesciences IPO is a main-board IPO of 2,88,75,000 equity shares of the face value of ₹1 aggregating up to ₹1,740.49 Crores. The issue is priced at ₹603 per share. The minimum order quantity is 24.
The IPO opens on June 16, 2017, and closes on June 20, 2017.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Eris Lifesciences IPO using UPI as a payment gateway. Zerodha customers can apply in Eris Lifesciences IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Eris Lifesciences IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Eris Lifesciences IPO opens on June 16, 2017 and closes on June 20, 2017.
Eris Lifesciences IPO lot size is 24, and the minimum amount required for application is ₹14,472.
You can apply in Eris Lifesciences IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Eris Lifesciences IPO will be done on Friday, June 23, 2017, and the allotted shares will be credited to your demat account by Wednesday, June 28, 2017. Check the Eris Lifesciences IPO allotment status.
The Eris Lifesciences IPO listing date is on Thursday, June 29, 2017.
Useful Articles
RHP